Results 41 to 50 of about 21,294 (218)

Clinical Implications of Variant ALK FISH Rearrangement Patterns [PDF]

Journal of Thoracic Oncology, 2015
Break-apart fluorescence in situ hybridization (FISH) is the FDA-approved assay for detecting anaplastic lymphoma kinase (ALK) rearrangements in non-small-cell lung cancer (NSCLC), identifying patients who can gain dramatic benefit from ALK kinase inhibitors.
Gao, Xin, Sholl, Lynette M., Nishino, Mizuki, Heng, Jennifer C., Jänne, Pasi A., Oxnard, Geoffrey R.   +5 more
openaire   +2 more sources

Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase (RTK) inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-a-, NTRK1-) non-small cell lung cancer globally?

Frontiers in Oncology, 2014
The discovery of anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) in 2007 and the approval of crizotinib for the treatment of advanced ALK-rearranged NSCLC in 2011 represents a landmark in the development of targeted ...
Sai-Hong Ignatius Ou
doaj   +1 more source

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor [PDF]

New England Journal of Medicine, 2010
Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK
James E, Butrynski, David R, D'Adamo, Jason L, Hornick, Paola, Dal Cin, Cristina R, Antonescu, Suresh C, Jhanwar, Marc, Ladanyi, Marzia, Capelletti, Scott J, Rodig, Nikhil, Ramaiya, Eunice L, Kwak, Jeffrey W, Clark, Keith D, Wilner, James G, Christensen, Pasi A, Jänne, Robert G, Maki, George D, Demetri, Geoffrey I, Shapiro   +17 more
openaire   +2 more sources

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma. [PDF]

, 2013
Background: Single arm phase 1 and 2 studies on Crizotinib in ALK-positive patients so far have shown rapid and durable responses. Spontaneous pneumothoraces as a result of response to anti-cancer therapy are rare in oncology but have been documented in ...
AT Shaw, BM O’Connor, EL Kwak, FA Shepherd, G Scagliotti, L Gandhi, M Mori, Mary ER O’Brien, R Arora, Riyaz Shah, Robert Thomas, RS Lai, S-H Yang, S-J Kim, Sanjay Popat, Spyridon Gennatas, Susana J Stanway, T Maniwa, Toon Min   +18 more
core   +1 more source

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. [PDF]

, 2017
The advent of genomics has led to the identification of specific "driver" mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions.
Bivona, Trever G, Neel, Dana S
core   +1 more source

Differential protein stability and clinical responses of EML4 - ALKfusion variants to various ALK inhibitors in advanced ALK - rearranged non-small cell lung cancer [PDF]

, 2017
BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibition using crizotinib has become the standard of care in advanced ALK-rearranged non-small cell lung cancer (NSCLC), but the treatment outcomes and duration of response vary widely.
Bayliss, Camidge, Choi, Choi, Eichenmuller, Eisenhauer, Heuckmann, Kwak, Lei, Li, Lin, Matikas, Oken, Palacios, Richards, Richards, Rikova, Sasaki, Seto, Shaw, Shaw, Smith, Soda, Soda, Solomon, Yoshida   +25 more
core   +1 more source

A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients.

PLoS ONE, 2013
BackgroundEML4-ALK fusion gene is found in only a small subset (2-6%) of non-small cell lung cancer. There is an urgent need to establish a rational diagnostic algorithm to identify this rare but important fusion in lung cancer.MethodsWe performed a ...
Kazuya Takamochi, Kengo Takeuchi, Takuo Hayashi, Shiaki Oh, Kenji Suzuki   +4 more
doaj   +1 more source

ALK rearrangement and overexpression in epithelioid fibrous histiocytoma [PDF]

Modern Pathology, 2015
Epithelioid benign fibrous histiocytoma, also known as 'epithelioid cell histiocytoma,' has traditionally been considered a morphologic variant of cutaneous fibrous histiocytoma (dermatofibroma). In addition to its characteristic epithelioid cytomorphology, several phenotypic differences suggest that epithelioid fibrous histiocytoma may differ ...
Leona A, Doyle, Adrián, Mariño-Enriquez, Christopher D M, Fletcher, Jason L, Hornick   +3 more
openaire   +2 more sources

PI3Kβ inhibition restores ALK inhibitor sensitivity in ALK-rearranged lung cancer [PDF]

, 2021
ABSTRACTFor non-small cell lung cancer (NSCLC) patients withALK-rearranged tumors, treatment with ALK inhibitors can improve outcomes. However, clinical resistance typically develops over time, and in the majority of cases resistance mechanisms are ALK-independent.
Talwelkar, Sarang S., Mäyränpää, Mikko I., Schüler, Julia, Linnavirta, Nora, Hemmes, Annabrita, Adinolfi, Simone, Kankainen, Matti, Sommergruber, Wolfgang, Levonen, Anna-Liisa, Räsänen, Jari, Knuuttila, Aija, Verschuren, Emmy W., Wennerberg, Krister   +12 more
openaire   +1 more source

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK. [PDF]

, 2016
Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein.
Burke, Amos, Camidge, David Ross, Damm-Welk, Christine, Fischer, Matthias, Harris, Michael, Hero, Barbara, Lehrnbecher, Thomas, Narayanan, Vignesh, Oschlies, Ilske, Pulford, Karen, Siddiqi, Faraz, Siebert, Reiner, Turner, Suzanne, Woessmann, Wilhelm   +13 more
core   +2 more sources